ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026
Associations between specific non-sustained ventricular tachycardia characteristics and sudden cardiac death in hypertrophic cardiomyopathy.
Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The second beat matters: coupling intervals and sudden cardiac death risk in hypertrophic cardiomyopathy.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
aimsNon-sustained ventricular tachycardia (NSVT) is a well-established risk factor for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). However, its characteristics have been overlooked. This study evaluates the prognostic value of NSVT characteristics, particularly coupling intervals, for HCM risk stratification. METHODS AND
resultsThis retrospective, multicentre study included 2625 HCM patients. Twenty-four-hour Holter recordings were assessed for NSVT and its characteristics (frequency, duration, and coupling intervals). The primary endpoint was SCD; the secondary endpoints were cardiovascular and all-cause death. Two thousand five hundred and eighty-four patients were analysed (49.6 ± 15.2 years; 62.4% male). Non-sustained ventricular tachycardia occurred in 320 (12.4%). During the median follow-up of 4.4 years, there were 221 all-cause deaths (8.6%), 159 cardiovascular deaths (6.2%), and 64 SCDs (2.5%). Among characteristics, the second coupling interval best predicted adverse outcomes (optimal cut-off = 394 ms). Non-sustained ventricular tachycardia frequency and duration were not prognostic. In univariable and multivariable analyses, a second coupling interval < 394 ms markedly increased the risk of SCD [hazard ratio (HR) 8.36, 95% confidence interval (CI) 4.33-16.12, P < 0.001], cardiovascular death (HR 3.64, 95% CI 2.07-6.37, P < 0.001), and all-cause death (HR 3.26, 95% CI 1.97-5.41, P < 0.001) vs. absence of NSVT, whereas a second coupling interval ≥ 394 ms did not. Replacing NSVT with malignant NSVT (NSVT with short second coupling interval) significantly improved SCD risk algorithms.
conclusionA short second coupling interval of NSVT poses a higher SCD risk in HCM than a long one. Detailed dissection of NSVT characteristics may improve decision-making for implantable cardioverter-defibrillator implantation in HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.